RE:Pfizer was once criticized for lack of vaccine developmentWhat excites me is the many possible products that can be developed over time. This has a multiple earnings growth potential. I will be adding some trading shares by year-end as I said before. However I won’t sell any before we start to record a positive P/E and EPS ratios. We just need that initial revenue stream and grow the company. Spayvac would just be the beginning .
Rich47 said “when they were once too focused on the covid vaccine by its shareholders. That is changing now. Biovaxys is now developing on many multiple fronts.”
“BioVaxys is also developing its own vaccines based on the patented liposome-based antigen delivery platform technology for multiple human indications in infectious disease, oncology, and allergy, with several programs in clinical development.”
https://stockhouse.com/news/press-releases/2024/11/20/biovaxys-partner-spayvac-for-wildlife-inc-scales-up-vaccine-production-capacity